<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Colorado institute pits world-class CAR T-cell expertise against aggressive lymphomas

minute read

by Nature | October 7, 2022
placeholder

The prognosis for lymphoma patients who don’t respond to chemotherapy has always been bleak. But new cellular therapies are transforming the field of cancer research, inspiring new hope for patients.

Topics: Press Coverage